Nutlin-3

製品コードS1061

Nutlin-3化学構造

分子量(MW):581.5

Nutlin-3は一種の有効で、選択性的なMdm2 (自身とp53に対するRING finger-dependent ubiquitin protein ligase) 拮抗剤で、無細胞試験でIC50値が90 nMですが、p53欠陥細胞中のp73を安定させられます。

サイズ 価格 在庫  
JPY 26637.78 あり
JPY 15838.68 あり
JPY 24477.96 あり
JPY 53275.56 あり
JPY 139668.35 あり

カスタマーフィードバック(4)

  • Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

     

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell death dis 2012 3, e294. Nutlin-3 purchased from Selleck.

  • Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

    d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

製品安全説明書

Mdm2阻害剤の選択性比較

生物活性

製品説明 Nutlin-3は一種の有効で、選択性的なMdm2 (自身とp53に対するRING finger-dependent ubiquitin protein ligase) 拮抗剤で、無細胞試験でIC50値が90 nMですが、p53欠陥細胞中のp73を安定させられます。
ターゲット
Mdm2 [5]
(Cell-free assay)
180 nM
体外試験

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 NXHETVJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\iXGg2yqEQvF2= NYTLNVV6PDkEoHi= Mly2Zoxw[2u|IEK3MW9JSy2rbnT1Z4VlKGOnbHygdJJwdGmoZYLheIlwdiClb33wZZJi[mynIITvJJRp[XRib3[gZoF{[WxibHX2[Yx{ MlmzNlY{PTB3NkW=
NP69 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTNzLk[5xtEzNjV2IN88US=> NF:1cIgzPjJ3MkW3OS=>
NP460 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJ{Lki1xtEyNjF6IN88US=> NX\uWGM4OjZ{NUK1O|U>
C666-1 NXm2VlZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTF7Lkm1xtE5Njl|IN88US=> NF7qV4ozPjJ3MkW3OS=>
C666-1 M3z1OWNmdGxiVnnhZoltcXS7IFHzd4F6 NV\kPXh5OTBiwsXN M1fVS|Q5KGh? NFvldoZFVVOR MnHXd4Vve2m2aYrld{BEPjZ4LUGgZ4VtdHNidH:geIhmKGO7dH;0c5hq[yCnZn\lZ5Qhd2ZiY3nzdIxifGmw NYLpN2FsOjZ{NUK1O|U>
C666-1  MYfGeY5kfGmxbjDBd5NigQ>? M2PvTVExKML3TR?= M1\i[lI1KGh? NGLDe4ZFVVOR MX;hZ5RqfmG2ZYOgeIhmKHB3MzDwZZRpf2G7LDD1dJJm\3WuYYTpcocheDV|LDDwNlEh[W6mIF3kcVI> MUmyOlI2OjV5NR?=
C666-1 Mm\qRZBweHSxc3nzJGF{e2G7 NGrkb|kyOCEEtV2= MXG0PE84OiCq MYnEUXNQ M{W0UZNmdnOrdHn6[ZMhSzZ4Nj2xJINmdGy|IITvJINqe3CuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> MnvFNlYzPTJ3N{W=
A549 NIe5dWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP2NlQhcA>? M{nDPGlEPTB;MUeuOlghyrFiND61NkDPxE1? MXuyOlEzPTJ|MB?=
A549-NTC NWXaUJN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVeyOEBp NFHRN4lKSzVyPUG5MlQzKMLzIEGuPVYh|ryP MnL4NlYyOjV{M{C=
A549-920 M4PoWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjZNlQhcA>? NYHaW4RKUUN3ME2zN{45PSEEsTC0Mlg1KM7:TR?= NE\lc3IzPjF{NUKzNC=>
CRL-5908 NGXGN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV6yOEBp NVGzOpZMUUN3ME2zPE44OSEEsTCyMlQ{KM7:TR?= NY\wcVBTOjZzMkWyN|A>
L6 NHLrUWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYKxNOKh|ryPwrC= NEjKOGYzPC92OD:3NkBp MlPwSG1UVw>? NWC0NWtucW6qaXLpeJMh[2WubIOgdJJwdGmoZYLheIlwdiCjbnSg[Iln\mW{ZX70bYF1cW:w MYeyOVg4OTd7NB?=
C2C12 NGHCUYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XOSVExyqEQvF5CpC=> M4jpbVI1NzR6L{eyJIg> NYDGcGRTTE2VTx?= Ml71bY5pcWKrdIOgZ4VtdHNicILvcIln\XKjdHnvckBidmRiZHnm[oVz\W62aXH0bY9v NFHQcpMzPTh5MUe5OC=>
MCF-7  NFrGWXZHfW6ldHnvckBCe3OjeR?= NIHOd28yOMLizszN M2XMdGROW09? MYTpcohq[mm2czDjfYNtcW5iREGgZY5lKESrY3XyxsA> MViyOVcxOjdyMx?=
DU4475  M1i0fmZ2dmO2aX;uJGF{e2G7 M3ToWVUwOTBxMkCg{txO NVPaTXB3OjUEoHi= NVTMWmdp\G:5boLl[5Vt[XSnczDUc4NiNTFiZH;z[UBl\XCnbnTlcpRtgQ>? MmKzNlU2PDdzN{S=
SMMC-7721 NILVb|FHfW6ldHnvckBCe3OjeR?= NFzmNGUyOCEQvF2= MnHqOFghcA>? M{fCZWROW09? M2\NZ4NifXOnczDEUmEhTFOEIHThcYFo\Q>? MUWyOVU1PDN4MR?=
SMMC-7721 MVPGeY5kfGmxbjDBd5NigQ>? NHjUd5IyOCEQvF2= NVrD[pJMPDhiaB?= NVW2flNCTE2VTx?= MYPpcoR2[2W|IITo[UBkcHKxbXH0bY4u[m:3bnSgdJJwfGWrbjDJSmkyPiC2bzDwZZJ1cWGubImgcI9k[WyrenWgbY4hfGinIHP5eI9xdGG|bdMg M4nudlI2PTR2M{[x
SMMC-7721 NWDqRVhmTnWwY4Tpc44hSXO|YYm= MWixNEDPxE1? MV60PEBp M2exbmROW09? NVe2WooxcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mxsBKTk6EMdMgcXJPSQ>? NXXnSo14OjV3NESzOlE>
SMMC-7721 MVXGeY5kfGmxbjDBd5NigQ>? NGDiVmYyOCEQvF2= M4LCOFM3KGh? NVW5fo0{TE2VTx?= MmXJZ4F2e2W|IITo[UBm[3SxcHnjJIV5eHKnc4Ppc44hd2ZiSV\JNVY> NXrT[2YzOjV3NESzOlE>
MCF-7 MlPOSpVv[3Srb36gRZN{[Xl? NFvtenMyOMLizszN MmTDNE0zPCCq MVXpcoR2[2W|IIC1N{BidmRicEKxM2NqeDF? MUmyOVQ5OjN5Mx?=
OVCAR10 MoXvSpVv[3Srb36gRZN{[Xl? NX74dXgyOTEEoN88US=> MmHONlFpyqB? MXjEUXNQ Ml:1bY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> MYKyOVQzPjV2OB?=
NCI-H23 MnrTSpVv[3Srb36gRZN{[Xl? MWKxNOKh|ryP NInTdJQzOWkEoB?= M1;rWGROW09? NUXxWmxkcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? Mlj4NlU1OjZ3NEi=
A2780 MmrwSpVv[3Srb36gRZN{[Xl? NW\SVWhZOTEEoN88US=> Mn\sNlFpyqB? NIW3fItFVVOR NVe1epM3cW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? Moe0NlU1OjZ3NEi=
NCI-H23 MX7GeY5kfGmxbjDBd5NigQ>? NGjwdFcyOMLizszN NHju[WMzOWkEoB?= MYjEUXNQ MWHk[YNz\WG|ZYOgeIhmKE[xeF2xJIxmfmWucx?= MWqyOVQzPjV2OB?=
A2780 M4\MbWZ2dmO2aX;uJGF{e2G7 MkHkNVDDqM7:TR?= NEnQVGEzOWkEoB?= NHTWcm1FVVOR M2nXWYRm[3KnYYPld{B1cGViRn;4UVEhdGW4ZXzz M3jkN|I2PDJ4NUS4
HCT116  MlrXSpVv[3Srb36gRZN{[Xl? M1WyZlExKML3TR?= NYntdGZlOjRiaB?= M1nxNoNifXOnczDhJJA2Oy2mZYDlcoRmdnRidHX0doFxdG:rZDDHNU1ienKnc4SgbY4h\GmybH;p[EBJS1RzMU[gZ4xwdmW|IFSzJIFv\CCGOB?= NYfabGFrOjV|OECwOVU>
MCF-10CA1a M2nWc2Z2dmO2aX;uJGF{e2G7 NXP3cpgzOTEEoN88US=> M33aVlQ5KGh? NWn3XGNHTE2VTx?= NVfmS|FocW6qaXLpeJMh[mG|YXygbY53[XOrb36gZY5lKHKnZIXj[YQhXEeILd8yN{1qdmS3Y3XkJIlvfmG|aX;uJJRwKGKjc3HsJIxmfmWucx?= MWSyOVI2Pzd{OR?=
MCF-10A1  MYDGeY5kfGmxbjDBd5NigQ>? M1nQVVExyqEQvF2= Mn3ONlQwPDhiaB?= MXzEUXNQ NEOwPGlqdmirYnn0d{BucWe{YYTpc44hd2Zibn;ycYFtKGK{ZXHzeEBmeGm2aHXsbYFtyqB? MX[yOVI2Pzd{OR?=
MCF-10CA1a NYK5e2JOTnWwY4Tpc44hSXO|YYm= MWixNOKh|ryP MWCyOEBp NEHoV41FVVOR MWPk[YNz\WG|ZYOgeIhmKFSJRj5OtlMucW6mdXPl[EBuWk6DIHzleoVteyCxZl3NVFItyqCPTWC5MEBidmUEoHnueIVoemmwwrFOtuKhOw>? NH;OcFMzPTJ3N{eyPS=>
MCF-10CA1a M2Dq[mZ2dmO2aX;uJGF{e2G7 NXXI[WpWOTEEoN88US=> NG\CdYgzPCCq Mo\RSG1UVw>? MkLibY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w MlX6NlUzPTd5Mkm=
SK-BR-7 NUPWcWdrTnWwY4Tpc44hSXO|YYm= M4DrNlExyqEQvF2= MmfqNlQhcA>? NFzQc5RFVVOR NV;EeXhpcW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u NIrnZ5QzPTJ3N{eyPS=>
SUM102PT MkTiSpVv[3Srb36gRZN{[Xl? NEDlTVUyOMLizszN NV7ZUXBTOjRiaB?= NV;0RWNXTE2VTx?= MYDpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? NX2yNoxxOjV{NUe3Nlk>
RAW 264.7 M17GcGZ2dmO2aX;uJGF{e2G7 NUC1cGlXOTEEoN88US=> MorFN|AhdWmw MnHYdJJmfmWwdIOgeIhmKHB3MzDy[YR2[3Srb36gbY4hemW|cH;ud4UhfG9iTGDT NF3ud|UzPTF5MkW0Oy=>
RAW 264.7 NFHL[GlHfW6ldHnvckBCe3OjeR?= Mn3nNVDDqM7:TR?= M3O3R|MxKG2rbh?= NXXl[JRLemWmdXPld{B1cGViTGDTMYF2\22nboTl[EB1cGViTl[t{tpDKGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBi[3Srdnn0fS=> NX3MWVZFOjVzN{K1OFc>
RAW 264.7 NUH3cVdjTnWwY4Tpc44hSXO|YYm= NWDpdlZOOTEEoN88US=> MlSxN|AhdWmw Mo\6bY5pcWKrdIOgUHBUNWmwZIXj[YQhVk9icILv[JVkfGmxbtMg M3[yb|I2OTd{NUS3
MCF7  NUDWbmRlS2WubDDWbYFjcWyrdImgRZN{[Xl? MmS2Nk42KML3TR?= NH3GfYk2KGR? MmrzSG1UVw>? MYHz[Y5{cXSrenXzJG1ETjdidH:gVGFTWCCrbnjpZol1cW:w MkLpNlUxQDV7MEK=
MCF7  NF7CS|VHfW6ldHnvckBCe3OjeR?= NV;aUI5COi53INM1US=> M4j5VFQ5KGh? M4LMNGROW09? MU\k[YNz\WG|ZYOgeIhmKGixbX;sc4dwfXNiRGPCJJJmeGGrcjDmdoVyfWWwY3nldy=> M3HKe|I2ODh3OUCy
ACHN MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGXRbWgxNjVvMUCg{txO MmDpNE03KGR? MkOxSG1UVw>? Mn33bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MUiyOVA3Pzd6Nx?=
Caki-2 Mk[0R4VtdCCYaXHibYxqfHliQYPzZZk> Ml\nNE42NTFyIN88US=> M3HsS|AuPiCm MkO0SG1UVw>? MVXpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M170RVI2ODZ5N{i3
A498 NFvJPXVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHm1[5cxNjVvMUCg{txO M4nrW|AuPiCm MVXEUXNQ MYDpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MV2yOVA3Pzd6Nx?=
115 MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{\UdlAvPS1zMDFOwG0> NYDJ[|NlOC14IHS= NGj5c3BFVVOR MlXHbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXeyOVA3Pzd6Nx?=
117 MmWwR4VtdCCYaXHibYxqfHliQYPzZZk> NXj0XmtrOC53LUGwJO69VQ>? NGHWXFkxNTZiZB?= NX\teZhJTE2VTx?= MV;pcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MWOyOVA3Pzd6Nx?=
ACHN M2P2cmZ2dmO2aX;uJGF{e2G7 M1zhVlAvPS9zL{Wg{txO MUm0PEBp MVHEUXNQ MlyycIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? M{jOPVI2ODZ5N{i3
Caki-2 M17O[WZ2dmO2aX;uJGF{e2G7 NFLjNlIxNjVxMT:1JO69VQ>? MkXpOFghcA>? NI\id|JFVVOR M3ztXYxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz NG\ZfYkzPTB4N{e4Oy=>
A498 Mn;kSpVv[3Srb36gRZN{[Xl? MlXRNE42NzFxNTFOwG0> NYK4cGhpPDhiaB?= MXPEUXNQ MXjs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? MoexNlUxPjd5OEe=
115 NXjDN4JOTnWwY4Tpc44hSXO|YYm= NF3Ge|YxNjVxMT:1JO69VQ>? Ml3rOFghcA>? MYXEUXNQ NFnDbXNt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= M3\uZVI2ODZ5N{i3
ACHN M4\ZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{noNlUh|ryP NGDBSHo1QCCq MmDTSG1UVw>? MlLlbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg NXXncJBROjVyNke3PFc>
Caki-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTNcJk6PSEQvF2= NGS4d4U1QCCq NIrkVohFVVOR M2\YS4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> MoLONlUxPjd5OEe=
A498 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljWOUDPxE1? M2LEVFQ5KGh? NVX4OndQTE2VTx?= NGLpcnJqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> MoPxNlUxPjd5OEe=
115 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jVd|Uh|ryP NXG1VVZUPDhiaB?= MVTEUXNQ MnjmbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg M1rEfFI2ODZ5N{i3
ACHN NGXLbWlHfW6ldHnvckBCe3OjeR?= MUW1JO69VQ>? NGC5OVA1QCCq NXfY[nQyTE2VTx?= M2jjTolv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= NXfsUHVKOjVyNke3PFc>
Caki-2 MnG3SpVv[3Srb36gRZN{[Xl? NGLkOnA2KM7:TR?= MUe0PEBp NFHkcFNFVVOR NFLn[mRqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg NIribm0zPTB4N{e4Oy=>
A498 NYTXNZdPTnWwY4Tpc44hSXO|YYm= MUe1JO69VQ>? NIrhW5Y1QCCq MYTEUXNQ MkjCbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= MX2yOVA3Pzd6Nx?=
115 NWP1boc2TnWwY4Tpc44hSXO|YYm= NHjnSXA2KM7:TR?= NIrONpA1QCCq NVPJe2hwTE2VTx?= MX3pcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi MlXqNlUxPjd5OEe=
MOLM-13 MYjGeY5kfGmxbjDBd5NigQ>? NXHsZ442PsLizszN MkO0NE05KGh? MX;EUXNQ NV\vc3JGcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdFU{NCCPRF2yMEBxOjFiYX7kJIFk\XS7bHH0[YQheDV| M4PkUlI1QDh3MEiy
MOLM-13 NFTHb2hHfW6ldHnvckBCe3OjeR?= NYPUNXJ3PsLizszN M2\3TFYhcA>? MmftSG1UVw>? NWi3UHc6\W6qYX7j[ZMhfGinIHHj[ZR6dGG2aX;uJI9nKGirc4TvcoUhUDKEIHHu[EBp\WG2IIPoc4NsKHC{b4TlbY5{KEi|cEK3JIFv\CCKc4C5NC=> NFzKdVEzPDh6NUC4Ni=>
HepG2 Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\TXoc4OiCq NGX3OXlFVVOR MWHJR|UxRTN3Lki2JOKyKDJwOTFOwG0> M4HqU|I1QDh2OEC5
HepG2/As NX3YXo9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVu3NkBp NYX5doFVTE2VTx?= NHTuNZFKSzVyPU[4MlE{KMLzIEmuOkDPxE1? M{HYR|I1QDh2OEC5
SMMC7721 M4Phcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrocXU4OiCq NGXQbYRFVVOR NX[2bmtpUUN3ME2zNU4zQCEEsTC0MlIh|ryP MoDwNlQ5QDR6MEm=
SMMC7721/Ac NHnmeYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoKzO|IhcA>? M1rhZ2ROW09? NUL5bndyUUN3ME21OU4zOSEEsTC1MlA{KM7:TR?= MmrsNlQ5QDR6MEm=
Huh-7 NIHSbWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYS3NkBp M2\OPGROW09? MmT5TWM2OD1|Mz65OkDDuSB|Lkmg{txO MV:yOFg5PDhyOR?=
Hep3B NYX4[5Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPQXndKPzJiaB?= MoPTSG1UVw>? MXnJR|UxRTJyLkG4JOKyKDFwOESg{txO MVuyOFg5PDhyOR?=
HepG2 MV3BdI9xfG:|aYOgRZN{[Xl? NF3lcYNqdmS3Y3XzJIFxd3C2b4Ppdy=> MVuyOFg5PDhyOR?=
SMMC7721 NYq2XG1uSXCxcITvd4l{KEG|c3H5 M4e0PYlv\HWlZYOgZZBweHSxc3nz NX\VZYFxOjR6OES4NFk>
Huh-7 M2fLTmFxd3C2b4Ppd{BCe3OjeR?= MoHvbY5lfWOnczDhdI9xfG:|aYO= MU[yOFg5PDhyOR?=
Hep3B M3fNfmFxd3C2b4Ppd{BCe3OjeR?= NGrvc4NqdmS3Y3XzJIFxd3C2b4Ppdy=> NEXodpQzPDh6NEiwPS=>
U2OS  MlXSSpVv[3Srb36gRZN{[Xl? NE\QfGczOCEQvF2= M1Pqc|I1KGh? NVLkPFFmcW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLiQlPMNmEyNCCEQ1zYUOKh[W6mQlPMWy=> MVeyOFg3PzJ3OR?=
AML2 MXjBdI9xfG:|aYOgRZN{[Xl? MmrNNk8yOCEQvF2= Mo\MNlQwPDhiaB?= NXrVRnNkcW6mdXPld{BieG:ydH;zbZM> MofkNlQ3PTl5NEm=
MOML13 MlnKRZBweHSxc3nzJGF{e2G7 M{TiWFIwOTBizszN NWfKc2JIOjRxNEigbC=> MkDpbY5lfWOnczDhdI9xfG:|aYO= NW\zN3Q2OjR4NUm3OFk>
AML2 M4P5bWZ2dmO2aX;uJGF{e2G7 M1zCTlEx|ryP M3XuTFIwPCCq M3rwXolv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz M1\YVVI1PjV7N{S5
AML3 NF2wOJZHfW6ldHnvckBCe3OjeR?= M2TxS|Ex|ryP NU\sNJdHOi92IHi= NIL5S2pqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> NYm0PGtbOjR4NUm3OFk>
MOML13 NY\hZnF1TnWwY4Tpc44hSXO|YYm= NEf0cGEyOM7:TR?= MoLZNk81KGh? MXXpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= NVfPUIFjOjR4NUm3OFk>
BeWo MlXsSpVv[3Srb36gRZN{[Xl? MUizNEDDvU1? M2LtUFI1KGh? MkTLbY5kemWjc3XzJJA2OyxiTXTtNkwheDJzIHHu[EBRfW2jIHH0JJRp\SCycn;0[YlvKGyndnXs NVLoOXpxOjR2OUixOVQ>
BeWo M1TNS2Fxd3C2b4Ppd{BCe3OjeR?= NXzy[nJQOzBiwsXN MXKyOEBp NWjZfnFIcW6lcnXhd4V{KGGyb4D0c5Nqew>? MUiyOFQ6QDF3NB?=
OCI MnrhSpVv[3Srb36gRZN{[Xl? NVnPeohCOTBizszN NF76R4YzPCCq NV3t[IxtfXC{ZXf1cIF1\XNidHjlJHNQS1NvMTDlfJBz\XO|aX;u MVyyOFQ4OzV4Mh?=
MOLM MoDZSpVv[3Srb36gRZN{[Xl? MkPSNVAh|ryP MXuyOEBp M3LsSZVxemWpdXzheIV{KHSqZTDTU2NUNTFiZYjwdoV{e2mxbh?= NInWOIkzPDR5M{W2Ni=>
U2OS  NW\u[2l6TnWwY4Tpc44hSXO|YYm= NWTqSopnOjBizszN MYeyOEBp MXjpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgTG8uOSCycn;0[YlvKGG|IIflcIwh[XNidHjlJJA2OyCycn;0[Ylv NHL2XFgzPDN4NkCwOy=>
RKO M37TcmZ2dmO2aX;uJGF{e2G7 M33JfVIxKM7:TR?= M13jb|I1KGh? M2iyVolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBJVy1zIIDyc5RmcW5iYYOge4VtdCCjczD0bIUheDV|IIDyc5RmcW5? MWGyOFM3PjByNx?=
U2OS  NFjxTFNHfW6ldHnvckBCe3OjeR?= NXPtcphqOjBizszN NXTq[4d4OjRiaB?= NUW0fFhucW6mdXPld{BJVy1zIHX4dJJme3Orb36gZZQhfGinIHzleoVtKG:oIITyZY5{[3KrcITpc44> MXiyOFM3PjByNx?=
RKO M2DlTmZ2dmO2aX;uJGF{e2G7 MlXENlAh|ryP MXqyOEBp NIT4bZZqdmS3Y3XzJGhQNTFiZYjwdoV{e2mxbjDheEB1cGVibHX2[Ywhd2ZidILhcpNkemmydHnvci=> MXqyOFM3PjByNx?=
SMMC-7721  M{nZfWNmdGxiVnnhZoltcXS7IFHzd4F6 MYSxMlI2NTJyIN88US=> NGDvd|UzPC92OD:3NkBp M1vsZ2ROW09? MUjpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= MlO3NlQzQDZ|MUK=
HuH-7 MorpR4VtdCCYaXHibYxqfHliQYPzZZk> NHXtdHEyNjJ3LUKwJO69VQ>? MoHlNlQwPDhxN{KgbC=> M1KxWmROW09? MYnpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= M3;jelI1Ojh4M{Gy
SMMC-7721  MV3BdI9xfG:|aYOgRZN{[Xl? M1y0XlIxKM7:TR?= M3H4[lQ5KGh? MVPEUXNQ NETmeIlqdmS3Y3XzJIFxd3C2b4Ppdy=> NHjBcVkzPDJ6NkOxNi=>
HuH-7 M3rMdWFxd3C2b4Ppd{BCe3OjeR?= NVTSUlhDOjBizszN MnnJOFghcA>? MWfEUXNQ MUPpcoR2[2W|IHHwc5B1d3Orcx?= MXmyOFI5PjNzMh?=
SMMC-7721  M1j6cWZ2dmO2aX;uJGF{e2G7 NX\mRld3OTBizszN MlmxN|YhcA>? MnnQSG1UVw>? Mn23[I94di2{ZXf1cIF1\XNidHjlJJBzd3SnaX6g[ZhxemW|c3nvckBt\X[nbDDv[kBxcG:|cHjvMXNmejN7Mj3wOVM> MVOyOFI5PjNzMh?=
HuH-7 NVz5bHBlTnWwY4Tpc44hSXO|YYm= NILGNHcyOCEQvF2= MnvlN|YhcA>? MUnEUXNQ MYDkc5dvNXKnZ4XsZZRmeyC2aHWgdJJwfGWrbjDlfJBz\XO|aX;uJIxmfmWuIH;mJJBpd3OyaH:tV4VzOzl{LYC1Ny=> Mk\2NlQzQDZ|MUK=
AT2 MXzGeY5kfGmxbjDBd5NigQ>? M2j1eVUwOTBizszN MoK2cIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? MlLxNlQzPDB{MEO=
REH NXTU[IhuTnWwY4Tpc44hSXO|YYm= MUe1M|ExKM7:TR?= NV62eWhLdGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= NECyVFczPDJ2MEKwNy=>
UoCB6 MXPGeY5kfGmxbjDBd5NigQ>? M1nYd|UwOTBizszN MV3s[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>? MoPHNlQzPDB{MEO=
AT2 MkH4R4VtdCCYaXHibYxqfHliQYPzZZk> MVewMVI2KM7:TR?= MXXpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MkDRNlQzPDB{MEO=
REH M1W2dGNmdGxiVnnhZoltcXS7IFHzd4F6 M2fmZlAuOjVizszN Mnq1bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NHjrS44zPDJ2MEKwNy=>
UoCB6 MkTLR4VtdCCYaXHibYxqfHliQYPzZZk> NGC4TlExNTJ3IN88US=> MmHxbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M4XoeFI1OjRyMkCz
A2780 MWXGeY5kfGmxbjDBd5NigQ>? MmTLOU8yOC9{MDFOwG0> MV2yOEBp M4n0VJVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi MmTCNlQyOzZzNEe=
H460 NGrQd4RHfW6ldHnvckBCe3OjeR?= NV3POpRXPS9zMD:yNEDPxE1? Mm[1NlQhcA>? Ml;CeZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? M1PUUlI1OTN4MUS3
Lovo  NFracohHfW6ldHnvckBCe3OjeR?= NGnlTZc2NzFyL{KwJO69VQ>? M3L4elI1KGh? MnLleZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? NXjie2UxOjRzM{[xOFc>
A2780 NIrjVoxCeG:ydH;zbZMhSXO|YYm= MmjJOU8yOC9{MDFOwG0> NHr6fmkzPCCq NFnBS|ZmdmijbnPld{BieG:ydH;zbZMhcW6mdXP0bY9vKGK7IFSyOllJN0VzOUXSJI93\XJicnjUVmFKVA>? M1WyZVI1OTN4MUS3
H460 MVnBdI9xfG:|aYOgRZN{[Xl? M1LEWVUwOTBxMkCg{txO MkHTNlQhcA>? NUXTb|Nb\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? Ml7RNlQyOzZzNEe=
Lovo  NWTaSY1iSXCxcITvd4l{KEG|c3H5 MnjiOU8yOC9{MDFOwG0> MX:yOEBp MXflcohidmOnczDhdI9xfG:|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=> MW[yOFE{PjF2Nx?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
細胞試験:

[1]

+ 展開
  • 細胞株: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • 濃度: Dissolved in DMSO, final concentrations ~ 30 μM
  • 反応時間: 8, 24, and 48 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • 製剤: Formulated in 2% Klucel, 0.5% Tween 80
  • 投薬量: 200 mg/kg
  • 投与方法: Orally, twice a day
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 581.5
化学式

C30H30Cl2N4O4

CAS No. 890090-75-2
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • 回答:

    It is a racemate.

Mdm2信号経路図

相関Mdm2製品

Tags: Nutlin-3を買う | Nutlin-3 ic50 | Nutlin-3供給者 | Nutlin-3を購入する | Nutlin-3費用 | Nutlin-3生産者 | オーダーNutlin-3 | Nutlin-3化学構造 | Nutlin-3分子量 | Nutlin-3代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID